Sofosbuvir / Velpatasvir

Rifampin

Contraindicated.

Available pharmaceutical opinion

Document made available to the pharmacist to communicate a drug interaction to the doctor.

DOWNLOAD
Mechanism

Rifampin may induce CYP 3A4 and P-gp and decrease the plasma concentration of Sofosbuvir / Velpatasvir.

Sofosbuvir / Velpatasvir

Pharmacodynamic effects

Possible decrease of clinical efficacy.

Recommendations

Do not administer with potent P-gp inducers or with moderate to potent CYP2B6, 2C8 or 3A4 inducers.

Alternative solution(s)

Rifampin

Pharmacodynamic effects

Recommendations

Association not recommended.

Alternative solution(s)

Monitor

Tests

Pharmacokinetic parameters
Parameters
Reference number
# patients
HCV
Dose
Frequency
AUC
Cmax
Sofosbuvir / Velpatasvir
3250
17/12
-
400/100 mg *
x 1 *
- 72%/- 82% †
- 77%/- 71% †
Rifampin
3250
17/12
-
600 mg
QD
 
 
Comment

Ref # 3250: * Administered as separate agents;
† GS-331007: AUC -5%; Cmax 23%.

Reference
  • 3250
    Sofosbuvir/Velpatasvir (Epclusa), Gilead Sciences, Ontario, Canada, 16 avril 2018.
  • 3082
    Garrison KL, Wang Y, Brainard DM, Sajwani K, Mathias A et al. The Effect of Rifampin on the Pharmacokinetics of Sofosbuvir in Healthy Volunteers. 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2014). Boston USA, November 7-11, 2014. Abstract 992.